(the following are excerpts from the south-west securities follow-up report for the 205q1 vaccine industry (with batches issued) in the original language)
Issuance of priority vaccines:
Mbs: 205 q1, noa, noa, noa, noa, noa, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no。
Pneumonia vaccine: 2025q1, 23 batches issued cumulatively (-30%), of which 13 batches of pneumonia vaccine were issued 19 batches (+0%), of which
Warson biological 9 batches, minami biological 6 batches and pfizer 4 batches. Four batches (71 per cent) of the 23-priced pneumonia vaccine were issued。
Hpv vaccine: 225 q1 batches issued 57 batches (+63%). Of these, 42 double-priced doses of hpv (+367 per cent) were issued, the demand for double-priced seedlings was growing rapidly, all of which came from vantaa; and the demand declined when mercado was issued 15 double-priced (-38 per cent)。
Vegetable herpes vaccine: 2025q1, 6 batches (-76%) of herpes vaccine were issued, all from gsk。
Influenza vaccine: 2025q1, 28 batches of flu vaccine at triple price (+460); one batch of influenza vaccine at tetravalent (-67 per cent)。
Vector virus vaccine: 21 batches (46%) of 2025 q1 rotavirus vaccine were issued。
Meningitis vaccine: 85 batches (-34 per cent) issued for 2025 q1 meningitis vaccine。
Issuance of other major vaccine varieties:
Human rabies vaccine: 223 batches (+37%) issued in 2025 q1。
Pox vaccine: 83 batches (-2%) of 205 q1 pox vaccine were issued。
Hib vaccine: 7 batches (-50%) issued in 2025q1。
Intestine virus vaccine: 2025q1, 4 batches (-69%) were issued for ev71。
Overall:
2025q1, most of the batches were issued down and some of them warmed up. Of these, the smart flying biological agent mercado 4 (hpv) and the nine-price hpv (hpv) resulted in the issuance of 0 batches, 15 batches (-38 per cent), 11 batches (-35 per cent) of the agent mercadon 5-priced round-of-virus vaccine and 8 batches (+100 per cent) of the self-study acyw 135 group of polysugar vaccine. Six batches (-40 per cent) of pneumonia vaccine were issued for the 13-priced population of minami (contai) and two batches (-40 per cent) of cell-obsolete combined vaccine and zero batches of 100-white-hib iv. 26 batches of hepatitis b vaccine (-13%) were issued by north china pharmaceuticals. Two-fold rabies vaccine batches were issued in concino, and one batch of the four-priced meningitis combination vaccine was achieved. The wanthai bivalent hpv vaccine achieved 42 batches (+74 per cent). Seven batches (+250%) of the orin biosorption tetanus vaccine were issued. 33 batches (+38 per cent) of 100 grams of biopox vaccine were issued; 0 batches of a nasal flu vaccine and 0 batches of a herpes vaccine were issued. The rabies vaccine (vero-cell) was used to produce 105 batches (+110%)。
Related targets: concino, contai biology, orin biology, pecker biology, conhua biology, hualand biology, dick king, north china pharmaceuticals, ji fei
It's a living thing, a living thing, a living thing。
Risk alerts: vaccine development falls short of expectations, risk of policy change, risk of safety of vaccine products。
